Management of Asymptomatic Chronic Hepatitis B with HBeAg Positivity

Diagnostic Steps

The American Association for the Study of Liver Diseases recommends quantifying HBV DNA by PCR immediately to determine disease phase and treatment need, as viral load combined with ALT determines whether antiviral therapy should be started 1
The Centers for Disease Control and Prevention recommends obtaining baseline alpha-fetoprotein (AFP) to assess for hepatocellular carcinoma at initial diagnosis, particularly important given the patient's age and transfusion history 2
The American Association for the Study of Liver Diseases recommends performing abdominal ultrasound to evaluate liver parenchyma and establish baseline for HCC surveillance 2
The European Association for the Study of the Liver recommends considering liver biopsy or non-invasive fibrosis assessment (FibroScan/elastography) if HBV DNA is elevated, as this will guide treatment decisions even with normal ALT 3

The American Association for the Study of Liver Diseases recommends initiating antiviral therapy immediately with entecavir 0.5 mg daily OR tenofovir (TDF or TAF) if any of the following are present: ALT elevation, age >30 years with persistently elevated HBV DNA, evidence of at least moderate fibrosis on biopsy or liver stiffness ≥9 kPa, or family history of HCC 1, 3, 4, 5
The Centers for Disease Control and Prevention recommends avoiding lamivudine due to high resistance rates 2, 1

The American Association for the Study of Liver Diseases recommends that all patients with chronic HBV infection require lifelong monitoring, even those with normal aminotransferase levels and those not on treatment 2
The Centers for Disease Control and Prevention recommends HBV DNA and ALT every 3-6 months to detect transition from immune-tolerant to immune-active phase, and HBeAg/anti-HBe status every 6-12 months to monitor for spontaneous seroconversion 2, 1
The American Association for the Study of Liver Diseases recommends HBV DNA every 3 months until undetectable, then every 6 months thereafter, and ALT/AST every 3-6 months to monitor treatment response in patients on antiviral therapy 1

The Centers for Disease Control and Prevention recommends beginning ultrasound screening every 6 months immediately for patients with high-risk criteria, including Asian men >40 years, Asian women >50 years, any patient with cirrhosis, family history of HCC, Africans >20 years, or age >40 years with persistent/intermittent ALT elevation and/or high HBV DNA 2, 1, 3
The American Association for the Study of Liver Diseases recommends measuring AFP every 6 months in conjunction with ultrasound for HCC surveillance 2

The American Association for the Study of Liver Diseases recommends vaccinating against hepatitis A immediately if anti-HAV negative, as HAV coinfection in chronic HBV patients increases mortality risk substantially 1
The Centers for Disease Control and Prevention recommends screening for coinfections, including anti-HCV, anti-HDV, and anti-HIV, and counseling on strict alcohol abstinence and vaccinating household and sexual contacts against HBV 1, 2